FDA Rejects Summit’s Ivonescimab Application; Shares Close at $14.15
Key Facts
Summit Therapeutics announced on November 15 that the U.S. Food and Drug Administration had issued a complete response letter for its ivonescimab application, after the regulatory action had been targeted for November 14, 2026. The application sought to use the drug with chemotherapy in patients with EGFR-mutated non-small cell lung cancer after prior treatment with tyrosine kinase inhibitors. STAT cited agency reviewers as saying that the absence of a demonstrated overall survival benefit “does not support a favorable benefit-risk profile that would support approval.” The regulatory hurdle therefore centered on whether the clinical dossier could demonstrate that the treatment extended patients’ lives, rather than on a standalone numerical estimate from the trial. Before the decision was announced, the company’s shares closed at $14.15 on November 13, after closing at $15.08 in the previous session.
The application was based on the HARMONi trial, which compared adding ivonescimab to chemotherapy with chemotherapy alone. In the primary overall survival analysis, with an April 2025 data cutoff, the hazard ratio was 0.79, with a 95% confidence interval from 0.62 to 1.01 and a p-value of 0.057; the result did not reach statistical significance. By contrast, the primary progression-free survival analysis showed a median of 6.8 months with the combination treatment, compared with 4.4 months with chemotherapy alone, and a hazard ratio of 0.52. Summit said the FDA viewed proof of a statistically significant overall survival benefit as necessary to support approval in this setting. It added that the progression-free survival results alone might not be sufficient to support marketing authorization, making the divergence between the two survival endpoints central to the application review.
The company also submitted an updated analysis with a June 2026 data cutoff. In the intention-to-treat population, the overall survival hazard ratio was 0.76, with a 95% confidence interval between 0.61 and 0.95 and a nominal p-value of 0.0151. Among Western patients, the hazard ratio was also 0.76, but the confidence interval extended from 0.52 to 1.10, a range that crosses 1 and does not establish a significant benefit in this group. An additional follow-up analysis among Western patients, using September 2025 data, had recorded a hazard ratio of 0.78, a confidence interval from 0.62 to 0.98 and a nominal p-value of 0.0332. These readings show variation in estimates across analyses and populations, while the confidence interval for the Western group in the June update remained wide around the hazard ratio estimate. Summit said it had made the updated data available to the FDA.
The complete response letter followed a review process that began with the application’s submission in the fourth quarter of 2025, followed by the agency’s acceptance in January 2026 and the setting of November 14 as the target action date. This sequence reflects that acceptance for filing allowed the review to begin, but did not constitute approval of the drug or its efficacy. The U.S. decision concerns the specific use studied in HARMONi: combination treatment for patients with EGFR-mutated lung cancer after prior treatment. The company also said it was continuing to develop the drug in trials for other tumors, without further details on their results or readout dates.
The decision came as funding resources strengthened Summit’s ability to continue its clinical program. AstraZeneca announced that it had completed a $2 billion investment in the company on October 5, 2026, and said the funding would accelerate development of ivonescimab with antibody-drug conjugates across tumor types. This is separate financial context from the application outcome and does not change the agency’s review conclusion for this use. In trading, Summit shares fell 6.14% to $14.15 in the Friday, November 13 session, then rose 0.14% to $14.17 in after-hours trading, according to Reuters via Yahoo Finance. Friday’s session preceded the announcement of the complete response letter on November 15, while the target regulatory action date was the day before the announcement. The available information does not include a later share price following the decision.